ValuEngine downgraded shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) from a sell rating to a strong sell rating in a research note issued to investors on Friday.

AVEO has been the topic of several other reports. FBR & Co reiterated an outperform rating and set a $3.00 price target on shares of AVEO Pharmaceuticals in a research report on Monday, February 27th. Zacks Investment Research cut AVEO Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, March 27th.

AVEO Pharmaceuticals (NASDAQ:AVEO) traded down 9.6694% during mid-day trading on Friday, reaching $0.7268. The company’s stock had a trading volume of 442,197 shares. The firm has a 50 day moving average price of $0.65 and a 200-day moving average price of $0.67. AVEO Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $1.09. The company’s market capitalization is $80.21 million.

AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). AVEO Pharmaceuticals had a negative return on equity of 286.18% and a negative net margin of 465.54%. The company had revenue of $2.53 million for the quarter. On average, equities analysts predict that AVEO Pharmaceuticals will post ($0.44) EPS for the current fiscal year.

WARNING: This piece was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/06/05/aveo-pharmaceuticals-inc-aveo-downgraded-to-strong-sell-at-valuengine.html.

In related news, major shareholder Equity Opportunities Iv Growth bought 6,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 28th. The shares were acquired at an average cost of $0.50 per share, for a total transaction of $3,000,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 5.10% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. NEA Management Company LLC boosted its position in shares of AVEO Pharmaceuticals by 57.9% in the first quarter. NEA Management Company LLC now owns 16,362,694 shares of the biopharmaceutical company’s stock worth $9,654,000 after buying an additional 6,000,000 shares during the last quarter. Perceptive Advisors LLC bought a new position in shares of AVEO Pharmaceuticals during the fourth quarter worth about $1,678,000. Sphera Funds Management LTD. bought a new position in shares of AVEO Pharmaceuticals during the first quarter worth about $1,711,000. New Leaf Venture Partners L.L.C. bought a new position in shares of AVEO Pharmaceuticals during the fourth quarter worth about $1,399,000. Finally, Sarissa Capital Management LP bought a new position in shares of AVEO Pharmaceuticals during the fourth quarter worth about $917,000. Institutional investors and hedge funds own 37.94% of the company’s stock.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Stock Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.